SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Bernard Arnault, billionaire chairman and CEO of global luxury goods company LVMH; such as Louis Vuitton. Long lost relatives ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

Attovia Therapeutics doses first participant in phase 1 study of ATTO-1310, its novel HLF anti-IL-31 ATTOBODY to treat chronic pruritus: Fremont, California Saturday, January 25, ...

Global stocks eased on Thursday, halting a rally sparked by U.S. President Donald Trump's mammoth spending plans for ...